Are there clinical studies showing that KY19382 can regrow hair in androgenic alopecia?

Androgenic alopecia, also known as male or female pattern baldness, is the most widespread form of hair loss. Current treatments such as minoxidil and finasteride are widely used, but both have limitations in effectiveness and tolerability. This gap has created interest in experimental molecules like KY19382. The compound has been reported in scientific literature as a potential stimulator of hair follicle regeneration. But the fundamental question remains: have clinical trials in humans proven that KY19382 regrows hair in androgenic alopecia?

**KY19382 is a small molecule developed in South Korea, designed to activate the Wnt/β-catenin signaling pathway. **

This pathway is essential for the development, regeneration, and cycling of hair follicles. In androgenic alopecia, hair follicles gradually shrink under the influence of androgens, especially dihydrotestosterone (DHT). By stimulating Wnt/β-catenin, KY19382 could theoretically push resting follicles back into the growth phase, a process known as anagen re-entry. These mechanistic claims are based on preclinical experiments rather than direct human testing.

What the Laboratory Research Shows

The main published study of KY19382 and hair is a 2021 paper by Ryu and colleagues in the British Journal of Pharmacology. The researchers tested KY19382 on human dermal papilla cells (the specialized cells at the base of each follicle that regulate hair growth), on human scalp follicles kept alive in the laboratory for 3 days, and on mice.

In the cells, KY19382 increased Wnt/β-catenin activity and markers associated with follicle activity, such as alkaline phosphatase. The cultured human follicles grew longer than untreated ones. In C57BL/6 mice treated on the skin daily for 14 or 28 days (5 mice per group), KY19382 produced more hair regrowth than minoxidil at 28 days, and in two other mouse models it led to the formation of new follicles. The paper discloses that the senior author is chief executive of CK Biotech, the company that holds the licence to develop the compound.

While these results are promising, they remain limited. The study used cells, short-term cultures of human follicles and small groups of mice, treatment lasted at most 28 days, and the evaluation methods were molecular markers, photographs and tissue analysis. No humans participated, and therefore no conclusions can be drawn about safety, dosing, or long-term outcomes in real-world conditions. Importantly, the physiology of mouse hair cycles differs significantly from that of humans. What works quickly in mice may not translate to the slower and more complex human hair cycle.

Are There Clinical Trials?

At present, there are no registered or published clinical trials of KY19382 in humans. A search of ClinicalTrials.gov in September 2026 found no studies of this compound. The absence of such trials means that key questions remain unanswered. We do not know whether KY19382 is safe when applied to human skin, whether it penetrates to the follicle in sufficient concentrations, whether it triggers side effects, or whether the hair regrowth seen in animals is reproducible in people.

The transition from animal research to human application is notoriously difficult. Many compounds that generate enthusiasm in preclinical studies never succeed in clinical trials. Differences in skin thickness, immune response, metabolism, and hair cycle length can all alter the outcome. Moreover, androgenic alopecia is a chronic and progressive condition, meaning that any real therapy must demonstrate both sustained regrowth and long-term safety. KY19382 has not yet met these benchmarks.

What We Need to Know Before Considering KY19382

If we were facing androgenic alopecia ourselves, the questions we would want answered are straightforward. Does KY19382 work on human follicles under real-world conditions? Can it regrow hair to a cosmetically meaningful degree? Is it safe for continuous use over years, given that androgenic alopecia does not resolve spontaneously? Until controlled human trials provide answers, KY19382 cannot be considered a proven therapy. At best, it is an experimental molecule with intriguing laboratory results but no demonstrated clinical benefit.

In response to the initial question: no, there are currently no clinical studies showing that KY19382 can regrow hair in androgenic alopecia. The only available evidence comes from preclinical work in mice and cell cultures, which is valuable for early discovery but insufficient for guiding treatment decisions in humans. For now, KY19382 remains an experimental candidate awaiting proper human trials.

References

Ryu, Y. C., Lee, D. H., Shim, J., et al. (2021). KY19382, a novel activator of Wnt/β-catenin signalling, promotes hair regrowth and hair follicle neogenesis. British Journal of Pharmacology, 178(12), 2533–2546. https://doi.org/10.1111/bph.15438 (PMID 33751552)

ClinicalTrials.gov. Search for "KY19382" (searched September 2026; 0 studies). https://clinicaltrials.gov/search?term=KY19382

U.S. Food and Drug Administration (FDA). (2025). Clinical trials and drug development. Retrieved from https://www.fda.gov/patients/drug-development-process/step-3-clinical-research

National Institutes of Health (NIH). (2025). Clinical trials overview. Retrieved from https://www.nih.gov/health-information/nih-clinical-research-trials-you

World Health Organization (WHO). (2025). Clinical trials. Retrieved from https://www.who.int/health-topics/clinical-trials